Olalekan Olatunde Fadebi is a PhD candidate in Medical Nuclear Science at the University of Pretoria’s Nuclear Medicine Research Institute (NuMeRI), where he investigates the genetic and molecular basis of metastatic prostate cancer in patients undergoing theragnostic treatment. He recently completed his MSc in Medical Oncology at the Pan African Cancer Research Institute (PACRI), elucidating the signalling mechanisms of a novel gene in Triple-Negative Breast Cancer. His research integrates genomics and clinical data to identify biomarkers that guide personalised cancer therapies, with a focus on African populations often underrepresented in precision medicine.
Fadebi's commitment to advancing cancer research earned him the Young Investigator Award from PACRI. He is a member of the American Association for Cancer Research (AACR), British Association of Cancer Research (BACR), and South African Society for Biochemistry and Molecular Biology (SASBMB). He is passionate about academic mentorship and aims to drive innovation in oncology and precision medicine across Africa.
CRDWC 2025
Oral Presentation